Video

Oral testosterone undecanoate shows promising results for first use in the real world

Author(s):

Urology Times staff
Conference|SMSNA Meeting

“We were surprised to see that the majority of subjects in these simulations had testosterone levels within eugonadal range for all 3 dose's studies,” says Jay Newmark, MD, MBA.

In this video, Jay Newmark, MD, MBA, discusses the background, findings, and takeaways of the study, “Real-World Experience with First FDA-Approved Oral Testosterone Undecanoate Formulation,” presented recently at the 2021 Sexual Medicine Society of North America Fall Scientific Meeting. Newmark is a chief medical officer at Clarus Therapeutics, Northbrook, Illinois.

Related Videos
Anne Pelletier Cameron, MD, FRCSC, FPMRS, answers a question during a video interview
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Modern medical office interior with computer and examination table | Image Credit: © New Africa - stock.adobe.com
Urinary bladder | Image Credit: © magicmine - stock.adobe.com
Related Content
Prostate Gland - (BPH) Benign Prostatic Hyperplasia | Image Credit: © Judith - stock.adobe.com
December 26th 2024

Top 10 BPH articles and videos of 2024

Benjamin P. Saylor
As the year comes to a close, we revisit some of this year’s top content on benign prostatic hyperplasia.
Former MLB player Dave Winfield shares lessons from baseball, philanthropy
November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff
In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.
Sandip Prasad, MD, on UGN-102’s potential as a non-surgical option in NMIBC
December 10th 2024

Sandip Prasad, MD, on UGN-102’s potential as a non-surgical option in NMIBC

Sandip M. Prasad, MD, MPhil
"The durability response for these patients was impressive given the fact that these patients were those who, by definition and by inclusion criteria, were recurrent within a year at [baseline]," says Sandip M. Prasad, MD.
blurred photo of a clinic hallway
May 28th 2023

2023 AUA highlights in benign urology

Urology Times staff
Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.
Gavel and Stethoscope on Reflective Table | Image Credit: © Andy Dean - stock.adobe.com
December 9th 2024

What drives malpractice lawsuits involving testicular cancer?

Benjamin P. Saylor
"We found that the majority of malpractice claims were filed in response to delayed diagnosis or treatment and no cases were filed in response to surveillance practices or surgical techniques," said Adri M. Durant, MD.
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
December 6th 2024

Gemcitabine-BCG shows early promise in BCG-exposed NMIBC

Benjamin P. Saylor
CR rate was 98% (39/40) at 3 months, 94% at 6 months (34/36), and 81% at 12 months (21/26).
© 2025 MJH Life Sciences

All rights reserved.